Integrating network pharmacology and experimental validation to decipher the mechanism of the Chinese herbal prescription modified Shen-Yan-Fang-Shuai formula in treating diabetic nephropathy

Context Diabetic nephropathy (DN) is the main cause of end-stage renal disease. Modified Shen-Yan-Fang-Shuai formula (M-SYFSF) has excellent clinical efficacy in treating diabetic kidney disease. However, the potential mechanism of M-SYFSF remains unknown. Objective To investigate the mechanism of M-SYFSF against DN by network pharmacological analysis and biological experiments. Materials and methods Utilizing a web-based pharmacology database, the potential mechanisms of M-SYFSF against DN were identified. In vivo experiments, male SD rats were injected with streptozotocin (50 mg/kg) and got uninephrectomy to construct a model of DN. M-SYFSF (11.34 g/kg/d) was gavaged once per day for 12 weeks after model establishment. In vitro experiments, human proximal tubular cells (HK-2) were performed with advanced glycation end-products (AGEs) (100 & mu;g/mL), then intervened with M-SYFSF freeze-dried powder. Pathological staining, WB, IHC, ELISA were conducted to explore the mechanism of M-SYFSF against DN. Results Network pharmacological analysis showed that MAPK pathway was the potential pathway. Results showed that compared with the Model group, M-SYFSF significantly reduced 24h urine albumin, UACR, and serum creatinine levels (54.90 & PLUSMN; 26.67 vs. 111.78 & PLUSMN; 4.28, 8.87 & PLUSMN; 1.69 vs. 53.94 & PLUSMN; 16.01, 11.56 & PLUSMN; 1.70 vs. 118.70 & PLUSMN; 49.57, respectively), and improved renal pathological changes. Furthermore, the intervention of M-SYFSF reduced the expression of pro-inflammatory cytokines and inhibited the activation of MAPK pathway in AGEs-treated HK-2 cells. Discussion and conclusion M-SYFSF is likely to reduce inflammation in DN by inhibiting the MAPK pathway. It provides a theoretical basis for the clinical application of M-SYFSF in the treatment of DN.

Automated summary

This study investigated the mechanism of the modified Shen-Yan-Fang-Shuai formula (M-SYFSF) against diabetic nephropathy (DN) through network pharmacological analysis and biological experiments. The results showed that M-SYFSF likely reduces inflammation in DN by inhibiting the MAPK pathway, providing a theoretical basis for its clinical application in the treatment of DN.